Literatur
-
1 Advanced Ovarian Cancer Trialists Group .Chemotherapy for Advanced Ovarian cancer. Issue 4 Cochrane Database of Systematic Reviews 2002
-
2
Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi M G, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F.
Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
J Clin Oncol.
1997;
15
1938-1944
-
3
Bristow R E, Tomacruz R S, Armstrong D K, Trimble E L, Montz F J.
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
J Clin Oncol.
2002;
20
1248-1259
-
4
Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart A M, Torri V, Williams C, Lissoni A, Bonazzi C. International Collaborative Ovarian Neoplasm (ICON) collaborators .
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer.
J Natl Cancer Inst.
2003;
95
125-132
-
5
Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M.
Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.
Gynecol Oncol.
2002;
85
71-80
-
6
du Bois A, Lück H J, Bauknecht T, Pfisterer J, Meier W.
2nd-line-Chemotherapie nach Platin- oder Platin-Paclitaxel-haltiger Primärtherapie beim Ovarialkarzinom: eine systematische Übersicht der publizierten Daten bis 1998.
Geburtsh Frauenheilk.
2000;
60
41-58
-
7
Du Bois A, Pfisterer J, Kellermann L.
Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland.
Gynäkologe.
2001;
34
1029-1040
-
8
du Bois A, Lück H J, Meier W, Adams H P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J.
A randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer.
J Natl Cancer Inst.
2003;
95
1320-1329
-
9
Gruppo Interregionale Cooperativo Oncologico Ginecologia (GICOG) .
Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer.
Gynecol Oncol.
1992;
45
115-117
-
10
McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M.
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and Stage IV ovarian cancer.
New Engl J Med.
1996;
334
1-6
-
11
Markman M, Hoskins W.
Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
J Clin Oncol.
1992;
10
513-514
-
12
Marth C, Trope C, Vergote I B, Kristensen G B.
Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
Eur J Cancer.
1998;
34
1175-80
-
13
Muggia F M, Braly P S, Brady M F, Sutton G, Niemann T H, Lentz S L, Alvarez R D, Kucera P R, Small J M.
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group Study.
J Clin Oncol.
2000;
18
106-115
-
14
Ozols R F, Bundy B N, Greer B E, Fowler J M, Clarke-Pearson D, Burger R A, Mannel R S, DeGeest K, Hartenbach E M, Baergen R.
Phase III Trial of Carboplatin and Paclitaxel compared with Cisplatin and Paclitaxel in patients with optimally resected stage III Ovarian cancer. A Gynecologic Oncology Group Study.
J Clin Oncol.
2003;
21
3194-3200
-
15
Piccart M J, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R J, Swenerton K D, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy J A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen J E, Zee B, Paul J, Baron B, Pecorelli S.
Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced ovarian cancer.
J Natl Cancer Inst.
2000;
92
699-708
-
16
Sandercock J, Parmar M KB, Torri V, Quian W.
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.
Br J Cancer.
2002;
87
815-824
-
17
Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K :.
Validity of complete paraaortic and pelvic lymphadenectomy in apparent stage I (pT1) ovarian carcinoma.
Proc ASCO.
2002;
801
-
18
The ICON and AGO Collaborators .
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial.
Lancet.
2003;
361
2099-2106
-
19
The International Collaborative Ovarian Neoplasm (ICON) Group .
Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
Lancet.
2002;
360
505-515
-
20
The Ovarian Cancer Meta-Analysis Project .
Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis.
J Clin Oncol.
1991;
9
1668-1674
-
21
Trimbos J B:.
Staging of early ovarian cancer and the impact of lymph node sampling.
Int J Gynecol Cancer.
2000;
10(S1)
8-11
-
22
Trimbos J B, Vergote I, Bolis G, Vermorken J B, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S ;. EORTC-ACTION collaborators .
European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
J Natl Cancer Inst.
2003;
95
113-125
Prof. Dr. J. Pfisterer
Universitätsklinikum Schleswig-Holstein
Michaelisstraße 16
24105 Kiel
